TQMC has acquired wide Domain Knowledge and Experience. You can FREELY access it here and here

DISCLAIMER: This matter here is a guide only. For authentic and up-to-date information, please contact TQMC.

The DIRECTIVES and STANDARDS listed here may have been subsequently REVISED . You must refer to the CURRENT REVISION and AMENDMENTS if any.

Thursday, January 7, 2010

Drug Redevelopment and Product Pipeline Enhancement

Drug Redevelopment and
Product Pipeline Enhancement 2010
Focusing on Innovative Strategies and External Partnerships to
Boost Productivity and Optimise the Product Pipeline
25th and 26th February, 2010: London, UK

marcus evans is proud to bring you the 2010 "Drug Redevelopment and Product Pipeline Enhancement Conference" – as an open business platform for the pharmaceutical and biotech entities to showcase their latest strategies and business models on generating revenue from existing compound arsenals.

This timely event will focus on exclusive insights into the reformulation strategies along with creating a long-awaited platform for discussion between the major players involved in drug-repositioning.

Attending This Premier marcus evans Conference Will Enable You to:
Explore novel indications for active clinical compounds
Optimise product life-cycle management through risk-adverse strategies
Examine the changing patent scenery in drug-development
Cut back R&D timeframe associated with drug re-development
Assess the latest formulation and regulatory standards on drug re-tasking
Expand product portfolios by re-targeting compounds for novel indications
Achieve effective product differentiation in a highly-competitive pharmaceutical market
Speed up regulatory procedures and increase project approval rates
Network with key industry players from pharma, biotech and drug delivery industries to capture the latest trends and key approaches

In the Chair
Day 1: Pietro Crovetto, Director Global Business Development, Teva Pharmaceuticals
Day 2: Dr. Bruce Pratt, Vice President Science Development, Genzyme Corporation
marcus evans Expert Speaker Panel:
Jutta Reinhard – Rupp Phd., Head of Innovation and Partnerships, Medical Science and Innovation, Merck Serono
Dr. Bruce Pratt, Vice President Science Development, Genzyme Corporation, US
Dr. Andrew Parsons, Vice President, CEED, Head of Preclinical Development, GlaxoSmithKline
Dr. Manuel Heim, Head Global Portfolio and Innovation Management, Acino Pharma
Arif Shivji, World Wide Business Development Principal, Pfizer
Aris Persidis, Ph.D., President, Biovista, Inc.
Katja Fastnacht, Manager External Cooperation and New Technologies, Abbott Laboratories
Lucette Doessegger, Global Head, Safety Licensing and Early Development, Roche
Sarah Carty, Director of Business Development, Elan Drug Technologies
Pietro Crovetto, Director Global Business Development, Teva Pharmaceuticals
Dr. Ronald Rooke, Director Immunopharmacology, Transgene
James McCormick, Associate Director Regulatory Affairs, Pharmaceutical Product Development (PPD)
Christina Furebring, Director Research and Development, Alligator BioScience
John Overington, Team Leader Chemogenomics, The European Molecular Biology Laboratory (EMBL)
Nasir Hussain, MBA, Phd., Ex-Head of Formulation, Glide Pharma Ltd

Learn from Key Practical Case Studies:
Merck Serono International discuss partnership opportunities and portfolio expansion strategies
Transgene bring in alternative indication routes for active clinical compounds
Genzyme Corporation explore partnering models and their utility in drug development
GlaxoSmithKline strengthen proof of concept while minimising R&D expenditure
Acino Pharma boost profit margins through opportunistic drug development
Alligator Bioscience optimise therapeutic proteins and ward off safety risks by drug redesign

Biovista, Inc.

For a full program, pricing and registration information please reply to this Email with "more info Drug Redevelopment" in the subject field.

Also of interest:

2nd Annual Immunogenicity
Assessing the Risk and Clinical Relevance of Immunogenicity in Biotherapeutics Development
14-15 January 2010: Avenida Palace Hotel, Barcelona, Spain

Key Topics
Understand and apply developments regarding EMEA and FDA guidelines for biotherapeutics
Interpret immunoassay results in the context of the study with a view to understanding the effect on the whole body
Translate clinical immunogenicity findings into risk assessments to ensure regulatory approval and profitability
Characterise clinical immune responses in the face of complicating factors such as concomitant therapies
Select the most promising leads for development with early-stage immunogenicity assessments
For a full program, pricing and registration information please reply to this Email with "more info Immunogenicity" in the subject field.

9th Annual Project and Portfolio Management for Pharma 2010
Growing Your Business and Maximising ROI and with Effective Project and Portfolio Optimisation in a Resource Constrained Environment
28-29 January 2010: Barcelona, Spain

Key Topics
Linking project and portfolio management with a company’s strategic function
Building the optimal portfolio in times of limited resources
Building project and portfolio management through alliance management
Organising projects and portfolio in SME pharma and biotech companies
Portfolio calculation and balancing
For a full program, pricing and registration information please reply to this Email with "more info Project & Portfolio Management" in the subject field.

Innovations in Medical Devices 2010
Excelling in R&D Strategies, Maximising NPD Output and Commercial Profit by Breakthrough Front-End Innovative Ideas and Methods
4-5 February 2010: Berlin, Germany

Key Topics
Improve long term innovation strategy
Master new R&D managing methods to shorten time-to-market
Increase efficiency of the NPD process and achieve overall product enhancement
Implement the effective risk analysis to avoid product failure
Diminish regulatory risks and avoid delays in NPD
For a full program, pricing and registration information please reply to this Email with "more info Medical Devices" in the subject field.


Please feel free to forward this email to any colleagues who you think might be interested in the events.

Mr Ola Samuelsson
Senior Marketing Manager
marcus evans
11 Connaught Place
London W2 2ET
Email pharmaconferences@marcusevansuk

No comments:

Post a Comment